- Home
- SLNO
as 08-01-2025 4:00pm EST
Soleno Therapeutics Inc is a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases. Its product candidate DCCR (Diazoxide Choline) Extended-Release tablets, is a proprietary extended-release formulation of a crystalline salt of diazoxide. DCCR has demonstrated the ability to activate the KATP channel in the brain, pancreas, and fat tissue.
Upcoming Earnings Alert:
Get ready for potential market movements as Soleno Therapeutics Inc. SLNO prepares to release earnings report on 06 Aug 2025.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 3.8B | IPO Year: | 2014 |
| Target Price: | $105.11 | AVG Volume (30 days): | 1.4M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.65 | EPS Growth: | N/A |
| 52 Week Low/High: | $41.50 - $90.32 | Next Earning Date: | 08-06-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 506.77% |
Latest Soleno Therapeutics Inc. News
SLNO Breaking Stock News: Dive into SLNO Ticker-Specific Updates for Smart Investing
Insider Monkey
a month ago
TD Cowen Starts Coverage Soleno Therapeutics (SLNO) Stock, Gives Buy
GlobeNewswire
a month ago
Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference
The Fly
a month ago
DoorDash, AMD upgraded: Wall Street's top analyst calls
MT Newswires
a month ago
TD Cowen Initiates Soleno Therapeutics at Buy With $110 Price Target
Insider Monkey
a month ago
Piper Sandler Reaffirms Overweight Rating on Soleno (SLNO) Driven by Strong VYKAT XR Prospects
GlobeNewswire
a month ago
Soleno Therapeutics Announces Multiple Presentations at the 2025 United in Hope: International Prader-Willi Syndrome Conference
Simply Wall St.
2 months ago
High Growth Tech Stocks in US for June 2025
Pharmaceutical Technology
2 months ago
EMA validates Soleno’s application for Prader-Willi syndrome treatment
Compare SLNO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "SLNO Soleno Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.